Novel Clinical Updates in Uremia
- PMID: 35807076
- PMCID: PMC9267798
- DOI: 10.3390/jcm11133791
Novel Clinical Updates in Uremia
Abstract
The progressive loss of kidney function is responsible for the retention of different metabolites due to a decrease in their renal clearance [...].
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Vanholder R., De Smet R., Glorieux G., Argiles A., Baurmeister U., Brunet P., Clark W., Cohen G., De Deyn P.P., Deppisch R., et al. Review on uremic toxins: Classification, concentration, and interindividualvariability. Kidney Int. 2003;63:1934–1943. doi: 10.1046/j.1523-1755.2003.00924.x. - DOI - PubMed
-
- Schroeder J.C., DiNatale B.C., Murray I.A., Flaveny C.A., Liu Q., Laurenzana E.M., Lin J.M., Strom S.C., Omiecinski C.J., Amin S., et al. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry. 2010;49:393–400. doi: 10.1021/bi901786x. - DOI - PMC - PubMed
-
- Saito H., Abe T., editors. Uremic Toxins and Organ Failure. 1st ed. Springer; Singapore: 2020.
Publication types
LinkOut - more resources
Full Text Sources